AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12621596
Drug: Pentagastrin (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentagastrin (0.1 micro g/kg)
Trial: 11188493
Drug: 0.56 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.56 g/kg of alcohol
Trial: 1415022
Drug: Interferon-alpha (IFN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-alpha (IFN alpha) therapy
Trial: 31130429
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment for symptomatic vertebral artery stenosis
Trial: 25686399
Drug: High-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oral tegafur-uracil (UFT) at 600 mg/day
Trial: 25686399
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no UFT treatment)
Trial: 25686399
Drug: High-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oral tegafur-uracil (UFT)
Trial: 21852010
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy plus radiation
Trial: 15266763
Drug: Clotrimazole 200
RxNorm normalized name: clotrimazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clotrimazole 200 mg vaginal tablets
Trial: 9875578
Drug: Live recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live recombinant canarypox-HIV-1 vaccine (given at days 0, 7, 14, and 21)
Trial: 9875578
Drug: Subunit gp120
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subunit gp120 vaccine (given at days 28 and 84)
Trial: 9875578
Drug: Unprimed controls
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unprimed controls (received two doses of subunit vaccine)
Trial: 7612066
Drug: Zinc sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulfate gel (Virudermin Gel)
Trial: 2116311
Drug: Felodipine 5-10
RxNorm normalized name: felodipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine 5-10 mg b.i.d.
Trial: 27611958
Drug: Mobile app
RxNorm normalized name: Mahana IBS CBT Mobile Application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile app treatment (Tät®) focused on pelvic floor muscle training (PFMT)
Trial: 27611958
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (postponed treatment)
Trial: 21649839
Drug: Fixed-dose amlodipine/olmesartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose amlodipine/olmesartan medoxomil (AML/OM) 5/20 mg, uptitrated to AML/OM 5/40 mg and 10/40 mg
Trial: 21649839
Drug: Fixed-dose amlodipine/olmesartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose amlodipine/olmesartan medoxomil + hydrochlorothiazide (HCTZ) 10/40+25 mg
Trial: 12673155
Drug: Ginseng (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginseng (400 mg.d‐1 of G115; equivalent to 2 g of Panax ginseng C.A. Meyer root material)
Trial: 1988829
Drug: Intravenous vidarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous vidarabine (30 mg/kg/day for 10 days)
Trial: 3987791
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg moclobemide
Trial: 6388247
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg moclobemide
Trial: 3987791
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg moclobemide
Trial: 27055414
Drug: 0.1% cyclosporine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% cyclosporine A cationic emulsion (CsA CE) eye drops, once daily
Trial: 15852492
Drug: Crocus sativus
RxNorm normalized name: CROCUS SATIVUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crocus sativus (saffron) 30 mg/day
Trial: 14607390
Drug: Antidepressant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant treatment (sertraline, phenelzine, or bupropion) for 8 weeks
Trial: 12884887
Drug: Desipramine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine (150 mg/d) plus buprenorphine (12 mg/d)
Trial: 12884887
Drug: Desipramine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine (150 mg/d) plus methadone (65 mg/d)
Trial: 1444728
Drug: Desipramine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine (150 mg/d)
Trial: 12884887
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus buprenorphine (12 mg/d)
Trial: 12884887
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus methadone (65 mg/d)
Trial: 6355500
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment with silver sulfadiazine cream
Trial: 27499517
Drug: Ocriplasmin 0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ocriplasmin 0.125 mg
Trial: 16006259
Drug: Vitamin supplementation
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin supplementation (folic acid 5 mg, pyridoxine 40 mg, cyanocobalamin 1 mg once daily for 3 months)
Trial: 16006259
Drug: No vitamin
RxNorm normalized name: Vitamin B12 NOS
DrugBank: Cyanocobalamin (DB00115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No vitamin treatment (control group)
Trial: 10390316
Drug: Oral nimodipine
RxNorm normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral nimodipine (30 mg every 6 hours)
Trial: 8683244
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose (HD) cisplatin 100 mg/m2
Trial: 8683244
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose (LD) cisplatin 50 mg/m2
Trial: 30344172
Drug: Patient-controlled intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled intravenous analgesia with tramadol
Trial: 30344172
Drug: Patient-controlled intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled intravenous analgesia with hydromorphone
Trial: 25247318
Drug: Erlotinib dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib dose escalation (150 mg, increasing by 50 mg every 2 weeks, maximum 250 mg)
Trial: 25247318
Drug: Standard-dose erlotinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose erlotinib (100 mg per day)
Trial: 25247318
Drug: Erlotinib dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib dose escalation
Trial: 25247318
Drug: Standard-dose erlotinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose erlotinib
Trial: 21809168
Drug: Aripiprazole (10-30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (10-30 mg/day)
Trial: 16180181
Drug: Propafenone (150‐300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone (150‐300 mg)
Trial: 16180181
Drug: Amiodarone (150‐450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone (150‐450 mg)
Trial: 12187545
Drug: L-arginine glutamate
RxNorm normalized name: L-Arginine L-glutamate
DrugBank: Arginine glutamate (DB13207)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine glutamate (6 g) plus yohimbine HCl (6 mg)
Trial: 12187545
Drug: yohimbine alone
RxNorm normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: yohimbine alone (6 mg)
Trial: 10442189
Drug: Postoperative RT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative RT and concomitant bolus FU administration with additional chemotherapy (FU 600 mg/m2/week x 6 + LV 500 mg/m2/week x 6) followed by pelvic RT with FU (400 mg/m2) during RT
Trial: 7617181
Drug: Copolymer 1
RxNorm normalized name: glatiramer (copolymer 1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copolymer 1 (20 mg daily subcutaneous injection for 2 years)
Trial: 2774639
Drug: Grenz rays
RxNorm normalized name: Ray Dol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grenz rays administered once weekly for 4 weeks
Trial: 30699155
Drug: Treatment-as-usual training
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual training
Trial: 25792303
Drug: Early individualised
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early individualised manipulative rehabilitation (twice a week for 4 weeks, 30 minutes per session)
Trial: 24933974
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with psychotropic medication plus valemidin
Trial: 24933974
Drug: Standard basic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard basic therapy plus valemidin
Trial: 12718225
Drug: Standard basic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard basic therapy
Trial: 17023230
Drug: Carvedilol CR
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carvedilol CR 20 mg
Trial: 17023230
Drug: Carvedilol CR
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carvedilol CR 40 mg
Trial: 20883227
Drug: Carvedilol CR
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carvedilol CR 80 mg
Trial: 10766415
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (Celin 500 mg) and Vitamin E (Evion 400 mg) for 90 days along with tamoxifen (10 mg twice a day)
Trial: 1486427
Drug: Tamoxifen treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen treatment alone
Trial: 3287972
Drug: Cefotetan (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotetan (single 2 g preoperative dose)
Trial: 3287972
Drug: Cefoxitin (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin (multiple 2 g perioperative doses)
Trial: 20826875
Drug: Pittsburgh Compound
RxNorm normalized name: Pittsburgh Compound B
DrugBank: Pittsburgh Compound B (DB15161)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pittsburgh Compound B (PIB) imaging
Trial: 17270055
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg OROS hydromorphone under fasting conditions
Trial: 17270055
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg OROS hydromorphone under fed conditions
Trial: 17270055
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg OROS hydromorphone under fasting conditions with naltrexone 50-mg block
Trial: 14982571
Drug: Remifentanil concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil concentration of 3 ng ml(‐1) until incision
Trial: 14982571
Drug: Remifentanil concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil concentration of 5 ng ml(‐1) for intubation
Trial: 14982571
Drug: Remifentanil concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil concentration of 10 ng ml(‐1) during intra-abdominal surgery
Trial: 14982571
Drug: Remifentanil concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil concentration of 5-7 ng ml(‐1) during closure
Trial: 6429359
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition in cachectic patients
Trial: 19239933
Drug: Mechanical preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical preparation of the colon (MPC)
Trial: 19239933
Drug: No mechanical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No mechanical preparation of the colon (No-MPC)
Trial: 9886106
Drug: Praziquantel (Thai
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel (Thai Government Pharmaceutical Organization) 40 mg/kg
Trial: 9886106
Drug: Biltricide 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biltricide 40 mg/kg
Trial: 9700743
Drug: CCK-4 (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCK-4 (0.5 mg/h)
Trial: 2916453
Drug: Obese children
RxNorm normalized name: Pediaclear Childrens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obese children after 6 months of treatment
Trial: 2916453
Drug: Lean children
RxNorm normalized name: Pediaclear Childrens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lean children after 6 months of treatment
Trial: 343992
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg tolmetin daily for 2 weeks
Trial: 343992
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg ketoprofen daily for 2 weeks after 1 week on placebo
Trial: 343992
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg tolmetin daily for 2 weeks
Trial: 31823525
Drug: Tropifexor (LJN452)
RxNorm normalized name: Tropifexor
DrugBank: Tropifexor (DB16343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropifexor (LJN452) 10-3000 µg single ascending doses (SAD)
Trial: 31823525
Drug: Tropifexor (LJN452)
RxNorm normalized name: Tropifexor
DrugBank: Tropifexor (DB16343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropifexor (LJN452) 10-100 µg multiple ascending doses (MAD)
Trial: 31823525
Drug: Tropifexor (LJN452)
RxNorm normalized name: Tropifexor
DrugBank: Tropifexor (DB16343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropifexor (LJN452) 300 µg with a high-fat meal
Trial: 25895447
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with 5-fluorouracil plus cisplatin
Trial: 23935969
Drug: Ixabepilone 40
RxNorm normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ixabepilone 40 mg/m² every 3 weeks (Group A)
Trial: 23935969
Drug: Ixabepilone 20
RxNorm normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ixabepilone 20 mg/m² on days 1, 8, and 15 every 4 weeks (Group B)
Trial: 25825853
Drug: No mechanical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No mechanical bowel preparation (No MBP)
Trial: 19046971
Drug: Combined feedings
RxNorm normalized name: SET,FEEDING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined feedings (tube feeding + oral feeding)
Trial: 16891292
Drug: bezafibrate (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bezafibrate (400 mg/d) for 6 months
Trial: 14763913
Drug: GH replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH replacement therapy (GHRT) at a starting dose of 0.45 IU (0.15 mg)/day, increased to 0.9 IU (0.30 mg)/day in month 2, and maintained at 2 IU (0.66 mg)/day
Trial: 8989178
Drug: Oral and
RxNorm normalized name: Tridate, oral and rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral and enteral ofloxacin-amphotericin B (group B)
Trial: 8989178
Drug: Oral and
RxNorm normalized name: Tridate, oral and rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral and enteral polymyxin E-tobramycin-amphotericin B (group C)
Trial: 8989178
Drug: Conventional antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional antibiotic regimen (control group A)
Trial: 8120739
Drug: levodopa/carbidopa (20/5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levodopa/carbidopa (20/5 mg)
Trial: 8120739
Drug: placebo (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (20 mg)
Trial: 3314221
Drug: Bivalent, live
RxNorm normalized name: poliomyelitis oral, bivalent, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent, live attenuated intranasally administered influenza A vaccine
Trial: 3314221
Drug: Inactivated, parenterally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated, parenterally administered influenza A vaccine
Trial: 29502281
Drug: Cognitive narrative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive narrative therapy intervention (four sessions: decision, subjectivation, metaphorization, projecting)
Trial: 18719318
Drug: Aspirin +
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin + thienopyridine
Trial: 15942767
Drug: Concurrent inspiratory
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent inspiratory and expiratory muscle training (CRMT)
Trial: 10484859
Drug: Morphine to
RxNorm normalized name: morphine Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine to Methadone ratio
Trial: 1752109
Drug: Alprazolam 0.003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam 0.003 mg/kg
Trial: 1752109
Drug: Alprazolam 0.007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam 0.007 mg/kg
Trial: 1752109
Drug: Alprazolam 0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam 0.02 mg/kg
Trial: 1752109
Drug: Alprazolam (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (all doses)
Trial: 27487783
Drug: Treatment condition
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment condition 1 (computer delivered risk assessment and feedback, nurse brief advice)
Trial: 27487783
Drug: Treatment condition
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment condition 2 (all elements of Treatment condition 1 plus biochemical feedback of infant SHS exposure)
Trial: 27487783
Drug: Treatment condition
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment condition 1
Trial: 27487783
Drug: Treatment condition
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment condition 2
Trial: 22588253
Drug: Expectancy of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expectancy of smoking THC in combination with active THC
Trial: 22588253
Drug: Active drug
RxNorm normalized name: Capillary active drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active drug and expectancy
Trial: 15899950
Drug: L-folic acid
RxNorm normalized name: cholecalciferol-folic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-folic acid (7.5 mg/d)
Trial: 2689790
Drug: micronized progesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: micronized progesterone administration
Trial: 320111
Drug: Oral zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral zinc sulphate as adjuvant treatment
Trial: 23583458
Drug: IV aminophylline
RxNorm normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV aminophylline 3 mg/kg
Trial: 45211
Drug: IV doxapram
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV doxapram 1 mg/kg
Trial: 21425378
Drug: Chicory coffee
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chicory coffee (300 mL daily for 1 week)
Trial: 17076917
Drug: Cognitive self-therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive self-therapy (CST)
Trial: 12562375
Drug: Removable implant
RxNorm normalized name: Super Spot Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Removable implant overdentures
Trial: 10982198
Drug: Fluoxetine (20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20-40 mg)
Trial: 1581012
Drug: Captopril (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25 to 50 mg, twice daily for 8 weeks)
Trial: 1581012
Drug: Metoprolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (50 to 100 mg, twice daily for 8 weeks)
Trial: 1581012
Drug: Hydrochlorothiazide (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (12.5 to 25 mg, twice daily for 8 weeks)
Trial: 29514649
Drug: Usual Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual Care + Moral Reconation Therapy (MRT)
Trial: 22313564
Drug: 0.15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg/kg dexamethasone
Trial: 27687360
Drug: Intraoperative superhydration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative superhydration of lactated Ringer's solution (30 mL/kg per fasting time)
Trial: 27687360
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of dexamethasone and intraoperative superhydration
Trial: 20397964
Drug: Sublingual zolpidem
RxNorm normalized name: zolpidem Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual zolpidem (Edluar) 10 mg
Trial: 20397964
Drug: Oral zolpidem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral zolpidem (Ambien) 10 mg
Trial: 18415895
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of cytotoxic agents with monoclonal antibodies
Trial: 11578917
Drug: Adjuvant and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant and neoadjuvant treatment regimens (Japan and West)
Trial: 9258576
Drug: Progesterone therapy
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Progesterone therapy (oral administration during the second luteal phase)